<DOC>
	<DOCNO>NCT00401895</DOCNO>
	<brief_summary>Coated stent different diameter presently commercially available , clinical study assessment best stent diameter well clinical efficacy , reduce number complication , effective portal pressure reduction ( essential treatment pathology TIPS indicate ) still exist . Aim study The purpose study compare clinical efficacy incidence complication TIPS create 8- 10-mm covered stent patient hepatic cirrhosis .</brief_summary>
	<brief_title>Transjugular Intrahepatic Portosystemic Shunt With 8- 10-mm Covered Stents</brief_title>
	<detailed_description>Clinical Efficacy Transjugular Intrahepatic Portosystemic Shunt With 8- 10-mm Covered Stents Cirrhotic Patients : A Randomized Controlled Study Introduction In treatment esophageal varix rebleeding1 ascites/hydrothorax refractory diuretic therapy2 transjugular intrahepatic portosystemic shunt ( TIPS ) , shunt stenosis ( occur 30-70 % case first post-procedural year ) onset hepatic encephalopathy ( 30-55 % case one year ) represent two major problem . Since year 2000 , new polytetrafluoroethylene cover stent highly improve TIPS patency , thus induce remarkable reduction rebleeding incidence . Some author , however , suggest maintenance shunt patency may involve increase risk hepatic encephalopathy , although data present literature limit controversial . The randomized control study3 available , fact , report low incidence hepatic encephalopathy patient treat covered stent compare treated conventional metallic stent . In preliminary experience,4 instead , similar incidence hepatic encephalopathy note group . In addition , group patient treat covered stent , high number case persistent intractable hepatic encephalopathy ( require shunt reduction ) recorded.5 Post-TIPS hepatic encephalopathy incidence increase decrease post-procedure portal pressure depend caliber stent use create anastomosis . This might suggest use covered stent small diameter aim reduce risk hepatic encephalopathy . Coated stent different diameter presently commercially available , clinical study assessment best stent diameter well clinical efficacy , reduce number complication , effective portal pressure reduction ( essential treatment pathology TIPS indicate ) still exist . Aim study The purpose study compare clinical efficacy incidence complication TIPS create 8- 10-mm covered stent patient hepatic cirrhosis . Methods All consecutive cirrhotic patient undergone TIPS Department bleed esophagogastric varix refractory medical endoscopic treatment ascites/hydrothorax refractory diuretic therapy consider eligible study . Before TIPS procedure , patient undergo complete clinical evaluation ( include psychometric test ) ass past present history hepatic encephalopathy ; Child-Pugh MELD score determine ; abdominal ultrasound esophagogastroduodenoscopies also carry . The patient randomize two group undergo TIPS either 8- 10-mm covered stent ( VIATORRÂ® , W. L. Gore &amp; Associates Inc. , Flagstaff , AZ ) . The two group follow accord post-TIPS protocol : - outpatient consultation one month post-procedure every three month thereafter clinically necessary . Each consultation include clinical exam , Child-Pugh MELD score determination , hepatic encephalopathy assessment ; - post-procedure ultrasound carry one four week , three six month , every six month thereafter case bleed recurrence ascites ; - follow-up esophagogastroduodenoscopy perform one week one month follow TIPS , every six month thereafter necessary ; - angiography do presence shunt dysfunction ( bleed ascites recurrence due portal hypertension ) case variceal recurrence risk bleed associate sign shunt dysfunction ultrasound . The following study end-points define : - hepatic encephalopathy incidence : hepatic encephalopathy grade evaluate accord modify West Haven Criteria . Those patient present grade II ( lethargy , apathy , personality change , inappropriate behavior , minimal disorientation time place ) high grade hepatic encephalopathy episode reach main study end-point ; - incidence persistent hepatic encephalopathy : define presence continuous mental state alteration , episodes worsen episode ; - incidence recurrent hepatic encephalopathy : define onset least three episode open hepatic encephalopathy six-month period ; - incidence variceal rebleeding : defined finding , esophagogastroduodenoscopy , ongoing recent variceal hemorrhage find blood stomach presence varix potential cause bleeding ; - shunt dysfunction : define find portosystemic gradient high 12 mm Hg angiographic evidence shunt stenosis occlusion ; - recurrence ascites : define need perform least one evacuation ascitic fluid paracentesis ; - survival : death cause record . All mortality occur within six-week period digestive bleeding episode consider related bleeding . All death occur within 30 day post-TIPS placement consider early mortality . Sample size The sample size calculate main study end-point : incidence hepatic encephalopathy . On basis previous study , post-TIPS incidence hepatic encephalopathy consider 50 % one year . To obtain clinically significant ( 50 25 % ) encephalopathy incidence reduction ( = 5 % b= 20 % ) therefore necessary enroll 57 patient per group . Randomization seal envelope block ten . Statistical analysis The comparability two group treat 8- 10-mm covered stent verify c2 Student t-test . The incidence hepatic encephalopathy ( main study end-point ) , shunt dysfunction , rebleeding , recurrence ascites , mortality ( secondary end-points ) calculate Kaplan-Meier method compare Log-rank test . The Number Cruncher Statistical System ( NCSS ) software employ . The rule guideline `` Good Clinical Practice '' legal requirement sensitive data storage experimental protocol follow . References 1 . Merli M , Salerno F , Riggio O , et al . Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotheraphy prevention variceal bleed cirrhosis : randomize multicenter trial . Hepatology 1998 ; 27 : 40-45 . 2 . Salerno F , Merli M , Riggio O , Cazzaniga M , Valeriano V , Pozzi M , Nicolini A , Salvatori F , GIST . Randomized control study TIPS versus paracentesis plus albumin cirrhosis severe ascites . Hepatology 2004 ; 40 : 629-635 . 3 . Bureau C , Garcia-Pagan JC , Otal P , Pomier-Layrgrargues G , et al . Improved clinical outcome use polytetrafluoroethylene-coated stent TIPS : result randomize study . Gastroenterology 2004 ; 126 : 469-475 . 4 . Angeloni S , Merli M , Salvatori F , De Santis A , Fanelli F , Pepino D , Attili AF , Rossi P , Riggio O. Polytetrafluorethylene-covered stent-graft TIPS procedure : 1-year patency clinical result . Am J Gastroenterol 2004 ; 99:280-285 . 5 . Riggio O , Nicolao F , Angeloni S , Masini A , Salvatori F , Fanelli F , Efrati C , Merli M. Intractable hepatic encephalopathy TIPS polytetrafluoroethylene-covered stent-graft . Scand J Gastroenterol 2003 ; 38:570-2 .</detailed_description>
	<criteria>All consecutive cirrhotic patient undergone TIPS Department bleed esophagogastric varix refractory medical endoscopic treatment ascites/hydrothorax refractory diuretic therapy consider eligible study . age &gt; 75 year ; past present history hepatic encephalopathy ; Zscore trial make testA ( TMTA ) &gt; 1.5 ; bilirubine level &gt; 5 mg/dl ; creatinine level &gt; 3 mg/dl ; serious cardiac pulmonary dysfunction ; ChildPugh 's score &gt; 11 ; model endstage liver disease ( MELD ) score &gt; 18 ; portal thrombosis ; diagnosis hepatic carcinoma ; sepsis ; spontaneous bacterial peritonitis ; renal insufficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT</keyword>
	<keyword>Covered stent</keyword>
	<keyword>portal hypertension</keyword>
	<keyword>hepatic encephalopathy</keyword>
</DOC>